32.2 C
Vientiane
Thursday, May 15, 2025
spot_img
Home Blog Page 2751

Art & Technology innovator 4ARTechnologies completes its unique ecosystem with secure NFT marketplace for physical and digital artworks

ZUG, SWITZERLAND – Newsaktuell – 25 May 2021 – 4ARTechnologies today announced the 4ART marketplace for NFTs and digital art, the newest module in their all-in-one tool. The 4ART marketplace is the space to offer and trade NFTs with a few clicks and provides the safest way for creators and collectors to make transactions with ease.




With the new international marketplace for NFTs, the 4ARTechnologies ecosystem is now even more complete. To meet the high standards for security and transparency, only 4ART minted NFTs can be traded on the integrated marketplace.

“Our technology makes it both very easy and very safe for creators and collectors to trade non fungible tokens from secured artworks.” – Kai Zeh, CTO 4ARTechnologies.

Features and benefits of the 4ART ecosystem include:

– Minting and securing the safest NFTs with a few clicks on any smart device

– Make transactions without the need of an extra crypto wallet

– Offer and trade directly on the integrated marketplace

– Experience and share physical and digital artworks together in the integrated VR showrooms

– Transfer to other marketplaces such as OpenSea, Nifty, Binance or Tezos

The marketplace will go online with NFT artworks by many 4ART artists, as well as international greats like Noah Becker. But also high end artworks were announced for the launch like the CryptoPunks.

The ability to mint and trade secure 4ART NFTs will be made available to selected artists in July, with full options and the complete marketplace becoming available to all users for the start of the next art market season in August 2021.

About 4ARTechnologies

With the goal of protecting the cultural heritage of art for future generations and bringing the global art market into the digital age, 4ARTechnologies is setting a new digital standard for the art world. The company combines the blockchain with its patented technology and offers all art world participants more transparency, security and efficiency.

https://www.4art-technologies.com/services

#4ARTechnologies

Laos Confirms 56 New Cases of Covid-19

Covid-19 update

Laos has confirmed 56 new cases of Covid-19, bringing the total number of cases to 1,878.

Han Ji-hyun Of SBD Entertainment, Wholly-Owned By Spackman Entertainment Group’s Associated Company, Spackman Media Group, Selected As Model For Shiseido Professional

  • Han Ji-hyun of SBD Entertainment, who starred in popular K-drama PENTHOUSE, endorses premium hair care brand, Shiseido Professional
  • Together with Han Ji-hyun, Shiseido Professional plans to actively develop various media marketing activities that include online and offline advertising
  • Previously, Han Ji-hyun won the Best Rookie Female Actor in the 2021 Brand Customer Loyalty Awards in Korea in April 2021

SINGAPORE – Media OutReach – 25 May 2021 – Spackman Entertainment Group Limited (“Spackman Entertainment Group” or the “Company” and together with its subsidiaries, the “Group“), one of Korea’s leading entertainment production groups, wishes to announce that Han Ji-hyun of SBD Entertainment Inc. (“SBD Entertainment“), a wholly-owned subsidiary of the Group’s associated company, Spackman Media Group Limited, was selected as a model for premium hair care brand, Shiseido Professional.

In collaboration with Han Ji-hyun of SBD Entertainment, Shiseido Professional plans to actively develop various media marketing activities that include online and offline advertising.

Han Hi-jyun of SBD Entertainment is set to continue to star in the third season of popular K-drama, PENTHOUSE.

Last month, Han Ji-hyun of SBD Entertainment was awarded the Best Rookie Female Actor in the 2021 Brand Customer Loyalty Awards in Korea which is held annually by the Korean Customers Council. Han Ji-hyun of SBD Entertainment was also featured alongside Lee Young-dae as twins from their characters in PENTHOUSE in the pictorial for Gucci in W Korea magazine.

Other than Han Ji-hyun, SBD Entertainment also represents Son Suk-ku who shall be starring in OTT media service Watcha’s original content, UNFRAMED PROJECT.

About Spackman Entertainment Group Limited

Spackman Entertainment Group Limited (“SEGL” or the “Company“), and together with its subsidiaries, (the “Group“), founded in 2011 by Charles Spackman, is one of Korea’s leading entertainment production groups. SEGL is primarily engaged in the independent development, production, presentation, and financing of theatrical motion pictures in Korea. According to Variety, Korea was the world’s fourth largest box office market in 2019, behind only North America, China and Japan.

The Group also invests into and produces Korean television dramas. In addition to our content business, we also own equity stakes in entertainment-related companies and film funds that can financially and strategically complement our existing core operations. SEGL is listed on the Catalist of the Singapore Exchange Securities Trading Limited under the ticker 40E.

Production Labels

SEGL’s wholly-owned Zip Cinema Co., Ltd. (“Zip Cinema“) is one of the most recognised film production labels in Korea and has originated and produced some of Korea’s most commercially successful theatrical films, consecutively producing 10 profitable movies since 2009 representing an industry leading track record. Recent theatrical releases of Zip Cinema’s motion pictures include some of Korea’s highest grossing and award-winning films such as CRAZY ROMANCE (2019), DEFAULT (2018), MASTER (2016), THE PRIESTS (2015), COLD EYES (2013), and ALL ABOUT MY WIFE (2012). For more information on Zip Cinema, do visit http://zipcine.com

SEGL also owns Novus Mediacorp Co., Ltd. (“Novus Mediacorp“), an investor, presenter, and/or post-theatrical distributor for a total of 79 films (58 Korean and 21 foreign) including ROSE OF BETRAYAL, THE OUTLAWS and SECRETLY, GREATLY, which was one of the biggest box office hits of 2013 starring Kim Soo-hyun of MY LOVE FROM THE STARS, as well as FRIEND 2: THE GREAT LEGACY. In 2012, Novus Mediacorp was also the post-theatrical rights distributor of ALL ABOUT MY WIFE, a top-grossing romantic comedy produced by Zip Cinema. In 2018, THE OUTLAWS, co-presented by Novus Mediacorp broke the all-time highest Video On Demand (“VOD“) sales records in Korea. For more information on Novus Mediacorp, do visit http://novusmediacorp.com.

The Company owns a 100% equity interest in Simplex Films Limited (“Simplex Films“) which is an early stage film production firm. The maiden film of Simplex Films, JESTERS: THE GAME CHANGERS (2019), was released in Korea on 21 August 2019. Simplex Films has several line-up of films including HURRICANE BROTHERS (working title).

The Company owns a 100% equity interest in Take Pictures Pte. Ltd. (“Take Pictures“) which produced STONE SKIPPING (2020) and THE BOX (2021), and shall release GUARDIAN (working title) in 2021 tentatively.

The Company owns a 100% equity interest in Greenlight Content Limited (“Greenlight Content“) which is mainly involved in the business of investing into dramas and movies, as well as providing consulting services for the production of Korean content. Through the acquisition of Greenlight Content, the Group’s first co-produced drama, MY SECRET TERRIUS, starring top Korean star, So Ji Sub, achieved #1 in drama viewership ratings for its time slot and recorded double digits for its highest viewership ratings. Greenlight Content was one of the main investors of MY SECRET TERRIUS.


The Company owns a 20% equity interest in The Makers Studio Co. Ltd., which plans to produce and release four upcoming films, the first of which will be THE ISLAND OF THE GHOST’S WAIL, a comedy horror film.

Our films are theatrically distributed and released in Korea and overseas markets, as well as for subsequent post-theatrical worldwide release in other forms of media, including online streaming, cable TV, broadcast TV, IPTV, video-on-demand, and home video/DVD, etc. We release all of our motion pictures into wide-theatrical exhibition initially in Korea, and then in overseas and ancillary markets.

Talent Representation

The Company holds an effective shareholding interest of 43.88% in Spackman Media Group Limited (“SMGL“). SMGL, a company incorporated in Hong Kong, together with its subsidiaries, is collectively one of the largest entertainment talent agencies in Korea in terms of the number of artists under management, including some of the top names in the Korean entertainment industry. SMGL operates its talent management business through renowned agencies such as MSteam Entertainment Co., Ltd. (Son Ye-jin, Lee Min-jung, Ko Sung-hee), UAA&CO Inc. (Song Hye-kyo, Yoo Ah-in, Park Hyung-sik), Fiftyone K Inc. (So Ji Sub, Ok Taec-yeon), SBD Entertainment Inc. (Son Suk-ku), and Kook Entertainment Co., Ltd. Through these full-service talent agencies in Korea, SMGL represents and guides the professional careers of a leading roster of award-winning actors/actresses in the practice areas of motion pictures, television, commercial endorsements, and branded entertainment. SMGL leverages its unparalleled portfolio of artists as a platform to develop, produce, finance and own the highest quality of entertainment content projects, including theatrical motion pictures, variety shows and TV dramas. This platform also creates and derives opportunities for SMGL to make strategic investments in development stage businesses that can collaborate with SMGL artists. SMGL is an associated company of the Company.

The Company owns a 100% equity interest in Constellation Agency Pte. Ltd. (“Constellation Agency“). Constellation Agency, which owns The P Factory Co., Ltd. (“The P Factory“) and Platform Media Group Co., Ltd. (“PMG“), is primarily involved in the business of overseas agency for Korean artists venturing into the overseas market. The P Factory is an innovative marketing solutions provider specializing in event and branded content production. PMG is a talent management agency which represents and manages the careers of major artists in film, television, commercial endorsements and branded entertainment.

Strategic Businesses

The Company owns a 100% equity interest in Frame Pictures Co., Ltd. (“Frame Pictures“). Frame Pictures is a leader in the movie/drama equipment leasing business in Korea. Established in 2014, Frame Pictures has worked with over 25 top directors and provided the camera and lighting equipment some of Korea’s most notable drama and movie projects including ITAEWON CLASS (2020), HOW TO BUY A FRIEND (2020), KIM JI-YOUNG, BORN 1982 (2019), FOUR MEN (2019) and ASADAL CHRONICLES (2019).

We also operate a café-lounge called Upper West, in the Gangnam district of Seoul and own a professional photography studio, noon pictures Co., Ltd.

For more details, do visit http://www.spackmanentertainmentgroup.com/

#SpackmanEntertainmentGroup

Xaysomboun Sees Over 10,000 Tourists in 2020

Future of tourism looks good for Xaysomboun

Xaysomboun Province received over 10,000 visitors in the first nine months of 2020, bringing USD 159,195 in revenue to the province.

Embark on a gastronomic journey to Korea at 7-Eleven with an all-new Korean menu from 7-SELECT

A selection of new and improved Korean-inspired dishes is launching island-wide across 7-Eleven stores on 26 May, with ingredients directly sourced from Korea. Look out for crowd-pleasing favourites such as Kimchi Jiggae and Jajangmyeon as well as the debut of an original and exclusive fusion sandwich!

 

SINGAPORE – Media OutReach – 25 May 2021 Next stop on 7-Eleven‘s culinary tour around Asia is Korea – the land of K-pop, K-beauty and of course, K-food! Say annyeonghaseyo to 7-Eleven’s range of new and tasty delights coming your way! Whether you’re looking for a light bite, a grab-and-go snack or something heartier, 7-Eleven has you covered.

Enjoy a taste of Korea with these all-new and improved additions to our menu

The first of our brand-new dishes is a family favourite in every Korean household and a must-order at Korean restaurants. 7-SELECT Kimchi Jiggae (Usual Price $4.50) is a Korean stew with a spicy kick, featuring kimchi and tofu in a chicken broth. Made with a generous serving of gochujang sauce brought in specially from Korea, this hug in a bowl is the perfect balance of sweet, sour and spicy flavours!

Another dish making its debut at 7-Eleven is 7-SELECT Korean Jajangmyeon (Usual Price $4). This popular and authentic dish boasts firm yet tender fresh egg noodles topped with chunjang – a black bean sauce imported from Korea – and fragrant spring onions for a salty yet slightly sweet taste.

If you’re looking for something truly unique, try a 7-SELECT Kimchi Chicken & Omelette Sandwich (Usual Price $3.50), a first-of-its kind Korean-inspired sandwich that includes a crunchy kimchi filling made from pickled onions, cabbage and carrots combined with light and fluffy egg omelette. This ideal breakfast bite or afternoon snack tastes great warmed up or chilled.

We’re also relaunching a popular item from our menu – if you liked our 7-SELECT Korean Spicy Rice Cakes (Tteok-bokki) (Usual Price $3.50) previously, you’ll love the improved recipe. We’ve now added spicy gochujang sauce and rice cakes imported directly from Korea for an even more authentic flavour. The packaging has also been given an upgrade allowing customers to reheat the contents more evenly and conveniently. From 26 May – 22 June 2021, you can also enjoy $0.50 off when you buy it with any featured 7-SELECT Korean item!

Quick and tasty K-food classics

Not forgetting these other Korean delights on the menu that are available from 2 Jun onwards:

7-SELECT Korean Army Stew (Usual Price $4.50) – a rich, spicy broth made with marinated chicken and noodles, topped with an array of vegetables and tofu. This hearty, satisfying dish will be sure to satisfy any hunger pangs you may have anytime throughout the day.

7-SELECT Bibimbap (Usual Price $3.90) – our take on one of Korea’s most popular and well-loved dishes. This delicious rice bowl is topped with vegetables, meat and egg as well as a sizeable serving of spicy gochujang sauce.

7-SELECT Chicken Bulgogi Wrap (Usual Price $2.90) a soft tortilla wrap filled with flavourful chicken marinated in ginger, garlic and soy sauce. Perfect if you’re in a hurry and need something quick to eat on the go.

For more detail on launch dates and the promotion, please refer to this summary table:

Product

RSP

Promotion

Promo Period

Launch Date

7-SELECT Kimchi Jiggae

$4.50

Get $0.50 off

7-SELECT Korean Spicy Rice Cakes with purchase of any other 7-SELECT Korean food items

26 May – 22 Jun 2021

26 May 2021

7-SELECT Korean Jajangmyeon

$4

7-SELECT Kimchi Chicken & Omelette Sandwich

$3.50

7-SELECT Korean Spicy Rice Cakes (Tteok-bokki)

$3.20

7-SELECT Korean Army Stew

$4.50

2 Jun 2021

7-SELECT Bibimbap

$3.90

7-SELECT Chicken Bulgogi Wrap

$2.90

More promotions and updates can always be found on the 7-Eleven Singapore Facebook page so stay tuned!

About 7-Eleven

Established in Singapore in 1983, 7-Eleven has since expanded to more than 400 stores island-wide to become the leading 24-hour convenience chain store. We take pride in serving the Singapore community 24 hours a day, 365 days a year. 7-Eleven emphasises convenience and value by offering a wide array of quality products, food and services to satisfy the needs of its customers. Think 7-Eleven and what comes to mind are the refreshing Slurpee, 7Café as well as a wide range of quality ready meals and sandwiches under 7-SELECT. 7-Eleven is also a 24/7 one-stop destination for customers who need to access bill payment services in their own time. Our services cover payment of utilities, courier services, and even cash withdrawal.

For more information, visit www.7-eleven.com.sg


#7-Eleven

Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results

  • Takeda’s dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important safety risks through three years following vaccination in ongoing pivotal Phase 3 TIDES trial
  • Regulatory filings for TAK-003 progressing in European Union and in many dengue-endemic countries; filing in United States planned for later this year
  • Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 390 million cases and 500,000 hospitalizations per year globally, with limited options for prevention

OSAKA, JAPAN, AND CAMBRIDGE, MASSACHUSETTS – Media OutReach – 25 May 2021 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual’s previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. TIDES enrolled more than 20,000 healthy children and adolescents ages four to 16 years in dengue-endemic countries in Latin America and Asia.

“Dengue epidemics occur suddenly, and hospitals can become overwhelmed with severe disease cases and people seeking testing,” said LakKumar Fernandoi, M.D., Center for Clinical Management of Dengue and Dengue Haemorrhagic Fever, Negombo General Hospital, Sri Lanka and a primary investigator of the TIDES trial. “Results from the long-term analysis of Takeda’s dengue vaccine candidate suggest that it could help with outbreak prevention, reduce rates of hospitalization and protect people from dengue regardless of their previous exposure. Importantly, no important safety risks were identified.”

Safety and efficacy results from the 36-month follow-up exploratory analysis of TIDES were presented on May 22, 2021, at the 17th Conference of the International Society of Travel Medicine (CISTM). Through three years (36 months after the second dose), TAK-003 demonstrated overall vaccine efficacy (VE) of 62.0% (95% CI: 56.6% to 66.7%) against virologically-confirmed dengue (VCD), with 65.0% VE (95% CI: 58.9% to 70.1%) in seropositive individuals and 54.3% VE (95% CI: 41.9% to 64.1%) in seronegative individuals. TAK-003 also demonstrated 83.6% VE (95% CI: 76.8% to 88.4%) against hospitalized dengue, with 86.0% VE (95% CI: 78.4% to 91.0%) in seropositive individuals and 77.1% VE (95% CI: 58.6% to 87.3%) in seronegative individuals. Observations of varied VE by serotype remained consistent with previously reported results. No evidence of disease enhancement was observed. TAK-003 was generally well tolerated, and there were no important safety risks observed. The results reinforce the potential of TAK-003 to help protect those who are living in or traveling to dengue-endemic countries.

“Our dengue vaccine candidate continued to provide protection against dengue throughout three years, and was especially robust in preventing hospitalization,” said Derek Wallace, VP, Dengue Global Program Leader at Takeda. “These results reinforce my confidence that TAK-003 can help address the significant global burden of dengue.”

As previously reported, the TIDES trial met its primary endpoint of overall VE against VCD at 12-months follow-up (VE: 80.2%; 95% CI: 73.3% to 85.3%; p<0.001) and all secondary endpoints for which there were a sufficient number of dengue cases (measured at 18-months follow-up). The TIDES trial has been amended to include the evaluation of a booster dose to address the waning of overall VE observed over time (from 12 through 36 months after the second dose), largely driven by outpatient dengue. Takeda intends to publish results of the 36-month exploratory analysis in a peer-reviewed journal this year.

TIDES safety and efficacy data through 36-months follow-up was included in regulatory submissions to the European Union and dengue-endemic countries and will be part of additional filings planned for 2021, including in the United States. Takeda will seek an indication for TAK-003 for the prevention of dengue disease in individuals four to 60 years of age, regardless of previous virus exposure, based on data in both adults and children. There remains a need for dengue vaccines that can be used in both dengue-naïve and dengue-exposed adults and children.

About TAK-003

Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses.1 Clinical Phase 2 data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegative participants, which persisted through 48 months after vaccination, and the vaccine was found to be generally safe and well tolerated.2 The pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial met its primary endpoint of overall vaccine efficacy (VE) against virologically-confirmed dengue (VCD) at 12-months follow-up and all secondary endpoints at 18-months follow-up for which there were a sufficient number of dengue cases, including VE against hospitalized dengue and VE in baseline seropositive and baseline seronegative individuals.3,4 Efficacy varied by serotype. The results demonstrated TAK-003 was generally well tolerated, and there have been no important safety risks observed to date.

About the Phase 3 TIDES (DEN-301) Trial

The double-blind, randomized, placebo-controlled Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial is evaluating the safety and efficacy of two doses of TAK-003 in the prevention of laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents.4 The TIDES trial is Takeda’s largest interventional clinical trial to date and enrolled over 20,000 healthy children and adolescents ages four to 16 years living in dengue-endemic areas. Study participants were randomly assigned to receive either TAK-003 0.5 mL or placebo by subcutaneous injection on Day 1 and Day 90.4 The study is comprised of five parts. Part 1 and the primary endpoint analysis evaluated vaccine efficacy (VE) and safety through 12 months after the second dose.4 Part 2 continued for an additional six months to complete the assessment of the secondary endpoints of VE by serotype, baseline serostatus and disease severity, including VE against hospitalized dengue.4 Part 3 is evaluating VE and long-term safety by following participants for an additional two and a half to three years.5 Part 4 will evaluate efficacy and safety for 13 months following booster vaccination and Part 5 will evaluate long-term efficacy and safety for one year after completion of Part 4.5

The trial is taking place at sites in dengue-endemic areas in Latin America (Brazil, Colombia, Panama, the Dominican Republic and Nicaragua) and Asia (Philippines, Thailand and Sri Lanka) where there are unmet needs in dengue prevention and where severe dengue is a leading cause of serious illness and death among children.4 Baseline blood samples were collected from all individuals participating in the trial to allow for evaluation of safety and efficacy based on serostatus. Takeda and an independent Data Monitoring Committee of experts are actively monitoring safety on an ongoing basis.

About Dengue

Dengue is the fastest spreading mosquito-borne viral disease and was one of the WHO’s top 10 threats to global health in 2019.6,7 Dengue is mainly spread by Aedes aegypti mosquitoes and, to a lesser extent, Aedes albopictus mosquitoes. It is caused by any of four dengue virus serotypes, each of which can cause dengue fever or severe dengue. The prevalence of individual serotypes varies across different geographies, countries, regions, seasons and over time.8 Recovery from infection by one serotype provides lifelong immunity against only that serotype, and later exposure to any of the remaining serotypes is associated with an increased risk of severe disease.

Dengue is pandemic prone, and outbreaks are observed in tropical and sub-tropical areas and have recently caused outbreaks in parts of the continental United States and Europe.9,10 Approximately half of the world now lives under the threat of dengue, which is estimated to cause 390 million infections and around 20,000 deaths globally each year.10,11 The dengue virus can infect people of all ages and is a leading cause of serious illness among children in some countries in Latin America and Asia.10

Takeda’s Commitment to Vaccines

Vaccines prevent 2 to 3 million deaths each year and have transformed global public health.12 For the past 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, COVID-19, Zika and norovirus. Takeda’s team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs. For more information, visit https://www.takedavaccines.com/.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

References

i Dr. LakKumar Fernando did not receive compensation for his statement.

1 Huang CY-H, et al. Genetic and phenotypic characterization of manufacturing seeds for tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis. 2013;7:e2243.

2 Tricou, V, Sáez-Llorens X, et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet. 2020. doi:10.1016/S0140-6736(20)30556-0.

3 Biswal S, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019;2019;381:2009-2019.

4 Biswal S, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomized, placebo controlled, phase 3 trial. Lancet. 2020. 2020;395:1423-1433.

5 ClinicalTrials.Gov. Efficacy, Safety and Immunogenicity of Takeda’s Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES). Retrieved March 2021.

6 World Health Organization. Factsheet. Dengue and Severe Dengue. April 2019. Retrieved February 2021.

7 World Health Organization. Ten threats to global health in 2019. 2019. Retrieved February 2021.

8 Guzman MG, et al. Dengue: a continuing global threat. Nature Reviews Microbiology. 2010;8:S7-S16.

9 Knowlton K, et al. Mosquito-Borne Dengue Fever Threat Spreading in the Americas. The Natural Resources Defense Council (NRDC). 2009. Retrieved February 2021.

10 Chan E, et al. Using web search query data to monitor dengue epidemics: a new model for neglected tropical disease surveillance. PLoS Negl Trop Dis. 2011;5:e1206.

11 Centers for Disease Control and Prevention. About Dengue: What You Need to Know. May 2019. Retrieved February 2021.

12 UNICEF. Vaccination and Immunization Statistics. 2019. Retrieved February 2021.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE: TAK ) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com .

#Takeda

With 3,500 Visitors Registered Already, Millésimes Alsace DigiTasting®, Unveils Its Programme!

HONG KONG SAR – Media OutReach – 25 May 2021 –

Launching Millésimes Alsace DigiTasting®, the first online trade show with real-life tastings organised by cross-industry experts, is a bold and innovative move by the French region of Alsace.


With the show only a few days away, the CIVA (Interprofessional Wine Board of Alsace) has published some preliminary statistics. And it’s a real success! CIVA also unveiled the programme of talks to take place during the show.


A record number of registrations!

Driven by the dynamism of Alsatian vineyards, the Millésimes Alsace Show will adopt an entirely new format this year by bringing together the physical and digital worlds. Participants will be able to enjoy the wines from the comfort of their own home. The tastings will be guided remotely by the producers’ live commentaries. This new format has been devised on an international scale and marks a page-turning moment for any vineyard and its PDO wines.

The show was an immediate success, right from the registration stage. After a week, the fair had already attracted more than 900 business visitors, topping its 2018 edition. To date, more than 3,500 visitors have already registered, with plenty more to come. Many French professionals have already registered, but the show seems to be even more successful beyond France’s borders. International visitors currently account for 70% of attendees and are from all over the world (almost 50 countries!) The top 5 most represented export markets are the UK, USA, Italy, Taiwan, and Canada. The news of the launch generated much excitement in Asia and throughout North America, as well as across Europe from west to east.

The attendees will be able to interact with any of the 100 exhibiting wineries via an integrated appointment booking system and video platform.

A series of talks designed for professionals!

In response to the expectations of industry professionals, the show will feature a series of three presentations, as part of its ‘interface of ingenuity and popularity’ (Carrefour des tendances) to provide the participants with more in-depth knowledge of Alsace’s vineyards. International speakers and Alsatian producers will host these talks:

– ‘New consumer trends: seize opportunities with Alsace wines’

– ‘Protecting people and nature: more than a trend, it’s a priority for Alsace.’

– ‘Alsace, an open-air showcase of all the soil types in the world.’

These presentations will be available in French, English, and Japanese and are for official participants only.

http://www.millesimes-alsace.com/

Facebook : https://www.facebook.com/vinsalsacedigitasting

Instagram : https://www.instagram.com/vinsalsacedigitasting

LinkedIn : https://www.linkedin.com/showcase/vinsalsacedigitasting

#MillesimesAlsaceDigiTasting #Digitasting #DrinkAlsace #VinsAlsace

Champasack, Savannakhet and Khammouane Provinces Ease Covid-19 Restrictions

Champasack Savannakhet and Khammouane Ease Covid-19 Restrictions (Photo: Phonexay Keovorajack)
Champasack, Savannakhet, and Khammouane ease Covid-19 restrictions (Photo: Phonexay Keovorajack)

Champasack, Savannakhet, and Khammouane provinces have eased certain Covid-19 measures, allowing residents to travel more freely and undertake their jobs.